BIO Submits Comments on FDA-Sponsor Communication
<p>
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on “Best Practices for Communication Between the Food and Drug Administration and Investigational New Drug Sponsors During Drug Development.”</p>
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on “Best Practices for Communication Between the Food and Drug Administration and Investigational New Drug Sponsors During Drug Development.” This docket represents an important step in identifying effective practices for communication during drug development, both through official meetings and less formal means of communication outside of established meetings. Modern drug development requires scientific collaboration by all parties in the innovation ecosystem, and promoting effective FDA-Sponsor communication is fundamental to our ability to translate scientific discoveries into safe and effective new therapies for patients.
